NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today highlights data presentations at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting being held in Miami, May 28 - 31, 2024. The analyses being presented provide important information about CAPLYTA’s efficacy, safety and tolerability profile in
Intra-Cellular Therapies, Inc. ( NASDAQ:ITCI ) investors will be delighted, with the company turning in some strong...
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q1 2024 Earnings Call Transcript May 7, 2024 Intra-Cellular Therapies, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and welcome to Intra-Cellular Therapies’ First Quarter 2024 Earnings Conference Call. At […]